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Summary The impact of leprosy and HIV co-infection is an evolving picture.
Surprisingly the outcomes that were feared, of more lepromatous disease has not
materialised. But with the roll-out of antiretroviral therapy, the emergence of leprosy
as Immune Reconstitution Inflammatory Syndrome is re-focusing attention on the
characteristics of this important co-infection.
Introduction
Co-infection with HIV has a major effect on the natural history of many infectious diseases,
particularly mycobacterial diseases such as tuberculosis. HIV infection causes loss of
effective cell mediated immunity allowing opportunistic infections to occur. Early in the HIV
epidemic it was predicted that HIV infection would worsen outcomes in leprosy patients with
more patients developing lepromatous disease and patients having fewer immune mediated
reactions. The limited published data on the epidemiological and clinical aspects of leprosy
suggest that the course of leprosy in co-infected patients has not been greatly altered by HIV
infection.1 In contrast, initiation of antiretroviral treatment (ART) has been reported to be
associated with presentation of new leprosy lesions and worsening of existing leprosy
lesions.2,3 In this review we discuss the published data on HIV/leprosy co-infection
highlighting new findings. The last major review on this co-infection was published before
widespread roll-out of anti-retroviral therapy. The effects of ART need to be considered when
reviewing any work on leprosy/HIV co-infection since ART profoundly alters the immune
response. It is therefore very important that when studies are reported they should indicate
whether patients are taking ART.
One new major observational study has been reported from Brazil.
Sarno and colleagues reported in 2008 on the largest HIV leprosy co-infection study to
date. This retrospective longitudinal cohort study in Brazil, followed 59 co-infected patients
and 967 leprosy only patients between 1996 and 2006. 37 (63%) of the HIV positive patients
received HAART. This study will be referred to in several sections below.
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In 1993, Professor Lucas reviewed the potential interactions between leprosy and HIV in
Leprosy Review.4 With the HIV pandemic established, previously uncommon mycobacterial
diseases, such as Mycobacterium avium complex and Mycobacterium tuberculosis were
becoming more common. This led to concerns that patients with leprosy might also be
affected by HIV, with increasing co-infection rate and severity of disease in co-infected
patients. He posed a series of questions about potential interactions and we shall use a similar
format here.
DOES HAVING HIV INCREASE THE RISK OF ACQUIRING M. LEPRAE INFECTION?
The few published small studies from the 1990’s provide limited data on the course of leprosy
in co-infected patients. HIV incidence was not increased amongst leprosy patients when
compared with patients without leprosy.5,6
The HIV epidemic has also now become so generalised and has affected many countries
where the two infections overlap including Brazil, Ethiopia and India without there being
marked increases in patients with leprosy and HIV. We can therefore conclude that being
HIV positive does not appear to increase the risk of developing leprosy.
DOES HAVING HIV ALTER THE CLINICAL FORM OF DISEASE?
It was predicted that HIV infection would cause patients to develop the lepromatous type of
disease. However all types of leprosy have been reported in co-infected patients; with two
East African studies from the early 1990’s reporting an increase in multi-bacillary (MB)
cases7,8 in contrast a Brazilian study reported a predominance of pauci-bacillary (PB) cases.9
Whilst these figures can only be interpreted in the context of data the pattern of leprosy types
in the populations from which these patients were drawn these reports suggest that HIV
infection has not increased the rate of lepromatous disease. The most contemporary data from
the Sarno group suggest that now, in HIV co-infected patients, tuberculoid disease is the
predominant form. In her cohort, 78% of co-infected patients had PB leprosy, compared to
50·6% in the HIV negative group. In comparison to the HIV negative group, the co-infected
group showed a higher rate of borderline tuberculoid leprosy (66·7% vs. 32·7%); a lower
mean BI at diagnosis and higher reaction rate at diagnosis. Most of the co-infected patients
were diagnosed with HIV before the leprosy. A lower CD4 count at HIV diagnosis was
associated with earlier manifestations of clinical leprosy. Of the 33 patients who had
viral load measured, leprosy diagnosis occurred when they had a lower viral load and higher
CD4 count.10
DOES HAVING HIV ALTER THE RESPONSE TO CHEMOTHERAPY?
It was feared that co-infected patients might have an impaired response to leprosy multi-drug
therapy. Co-infected patients treated with standard length WHO-MDT regimens have
responded adequately. However the Sarno study observed a 3·4% relapse rate in co-infected
patients on ART compared to the 1·0% relapse rate in HIV negative patients.10 This suggests
that patients with co-infection should be monitored more closely for relapse after treatment.
This should also be a marker that is closely monitored.
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DOES HAVING HIV ALTER THE INCIDENCE OF REACTIONS
AND NERVE DAMAGE?
It was predicted that since reactions and nerve damage are immune-mediated events the
incidence of these in co-infected patients might be decreased.
A 1994 Ugandan study looking at 12 HIV seropositive and 40 seronegative MB patients,
reported that MB leprosy patients with HIV had an increased risk of developing Type 1
Reactions.11 However data from the large ALERT MDT Field Evaluation Study (AMFES)
study in Ethiopia, suggested that HIV infection (n ¼ 22) was not a risk factor for developing
reversal reactions (both acute and chronic), although HIV patients did seem to be at higher
risk of recurrent reversal reactions (RR 2·2, 95% CI 0·98–4·7).12
The most contemporary data comes from Sarno et al. where patients with HIV
co-infection were more likely to be in reaction at diagnosis (31·5% vs. 18·8%).
However, during the surveillance period the rates of reaction in the two groups were similar
(59·3% vs. 53·1%).10
There is very little data on ENL in co-infected patients, The AMFES study reported a
higher risk of ENL reactions (RR 5·2, 95% CI 1·7–15·9) but only 3 patients were affected.12
Thus a picture is emerging of patients being at higher risk of developing reactions,
especially when they are on ART.
Patients with HIV are also at risk of developing peripheral nerve damage including
generalised peripheral neuropathy and mono-neuritis multiplex through several mechanisms,
namely, treatment with antiretrovirals and HIV infection per se. It was assumed that HIV
co-infection would worsen nerve damage in leprosy patients. There were a few small studies
in the 1990 which did not find increased nerve damage in co-infected patients.11,12 A well
designed prospective study of peripheral nerve function using sensitive tools to detect nerve
damage in co-infected patients is needed to establish whether these patients do have increased
rates of nerve damage both at diagnosis and at follow up (Table 1).
DOES HAVING HIV ALTER THE PATHOLOGY OF LEPROSY LESIONS?
It was predicted that co-infected patients would have more lepromatous type disease. Patients
with tuberculoid leprosy have a good cell-mediated immune response to M. leprae resulting
in a few skin lesions which histologically have well organised lymphocyte (CD68 þ ,
CD3 þ , CD8 þ , CD4 þ ) rich granulomas with predominantly CD4 T cells. In contrast,
patients with lepromatous leprosy show poor or absent cell-medicated immunity towards
Table 1. Summary of impact of HIV-1 on leprosy: expected vs. actual
Theory In practice
Epidemiological Incidence Increase in leprosy No change
Clinical Lepromatous leprosy Increase No change
Treatment response Worsened No change
Type-1 reactional states Fewer Increased
Neuritis Worsened ?
Novel findings Presentation as IRIS
Histopathological Granuloma formation Decreased No change
Bacterial Index Increased No change
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M. leprae, resulting in uncontrolled growth of bacilli and disseminated skin lesions.
Histological examination of biopsies from their lesions reveals that the granulomas are
comprised of macrophages and a small numbers of CD8 T cells.9 HIV affects cell-mediated
immunity, and it was initially expected that, just as inM. tuberculosis infection, the decrease
in CD4 cells would result in decreased capacity for mycobacterial containment and thus an
increase in disseminated disease. But a Brazilian study by Sampaio and colleagues (1995)
shows that HIV co-infected patients with borderline tuberculoid lesions CD4 counts, had
lesions with well formed granuloma and normal CD4 cell numbers in their lesions even
though they had low circulating CD4 counts. Co-infected patients with lepromatous leprosy
lesions had loose infiltrates comprising of heavily parasitized macrophages and a small
number of almost exclusively CD8 lymphocytes, which is similar to HIV negative patients.13
Deps and Lucas (pers comm.) have also looked at a series of patients with co-infection and
used a standardised methodology to assess the pathology of the skin lesions. Again all
types of leprosy were seen and the lesions had histology that was typical for the leprosy type.
There was some suggestion that the lesions from patients with active BT leprosy displayed
compact granulomas, oedema and necrosis. This is compatible with up-regulation in BT
leprosy. Thus evidence is accumulating for HIV/leprosy co-infection being associated with
immune activation rather than immune paresis. It is surprising that M. leprae can attract
CD4 þ cells out of the circulation into leprosy skin lesions.
DOES HAVING LEPROSY WORSEN HIV INFECTION?
This is a difficult aspect to research since it is critically affected by the timing of HIV
infection and the presence not just of leprosy but also other opportunistic infections. No
clinical data has suggested that leprosy would worsen HIV infection. However Carvalho et al.
(2008) looked at 28 Brazilian patients and found that the co-infected group (n ¼ 7)
had lower CD4:CD8 ratios, higher levels of CD8 þ activation, increased Vd1:Vd2 T cell
ratios and decreased percentages of plasmacytoid DCs as compared to HIV-1 mono-infected
patients.14 As these are all recognised features of progressive HIV disease, so leprosy
co-infection may aggravate HIV pathogenesis and this is another area that deserves close
monitoring.
The exact immune-pathological mechanism underlying the possible increase in frequency
of leprosy reactions is not clear. Dysregulation of the immune system and the heightened state
of immune activation in HIV infection may be responsible. In addition, delayed clearance of
M. leprae antigens due to the impaired phagocytic function of macrophages has also been
implicated.
HOW DOES ART AFFECT LEPROSY/HIV CO-INFECTION?
Since the introduction of highly active antiretroviral therapy (HAART) in the management
of HIV, especially in regions endemic for leprosy, leprosy is being increasingly reported as
part of the Immune Reconstitution Inflammatory Syndrome (IRIS).
IRIS is a paradoxical deterioration in clinical status after starting HAART, a deterioration
that is attributable to the recovery or reactivation of someone’s immune response to a latent
or sub-clinical process. The HAART regimes currently used increase production and
redistribution of CD4 þ cells’ improved pathogen specific immunity, both to HIV and other
pathogens. While improved immunity to HIV is the required effect from HAART, improved
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immunity to other opportunistic pathogens or development of autoimmunity can result in
IRIS. The prevalence of IRIS in cohort studies of HIV positive patients ranges from 3% to
more than 50%, varying greatly with the AIDS-defining illness affecting the patient at the
start of HAART therapy.15 Risk factors for the development of IRIS include advanced HIV
disease with a CD4 þ T cell count under 50 cells/mm, unrecognised opportunistic infection
or high microbial burden, and the number and presence of prior opportunistic
infections. HAART triggers overt clinical manifestations of co-infection with tuberculosis
(pneumonitis and lymphadenitis), MAC (lymphadenitis), cytomegalovirus (retinitis), herpes
zoster, C and B hepatitis virus, leishmania and now leprosy.16
Since 2003, 23 reports of patients developing leprosy as IRIS have been
published.2,3,13,14,17,18 These were recently reviewed by Deps and Lockwood. The cases
have been reported from areas where ART is more readily available so 70% were from S
America (58% Brazil) and 20% from India. Borderline leprosy was the commonest form and
T1R was always present. Ulceration, a highly unusual feature in leprosy lesions, was
observed in 6 patients. It may be that the high proportion of borderline tuberculoid leprosy
cases among the HIV-infected patients on HAART could shed light on the questions related
to the kinetics of M. leprae infection and development of disease. Conversely, the high
frequency of PB patients, low bacillary load and reactions among HIV-infected indivi-
duals, could be simply due to an earlier-than-usual detection of the disease in immune-
reconstituted patients.
A case definition for leprosy-associated IRIS, has been proposed to facilitate correct
identification of cases.19 For patients to have leprosy associated IRIS they have to have the
following features: (1) leprosy and/or leprosy reaction presenting within 6 months of starting
HAART; (2) advanced HIV infection; (3) a low CD4 þ count before starting HAART;
(4) CD4 þ count increasing after HAART has been started. Subdividing leprosy- associated
IRIS into groups according to data on timing and clinical presentation may help towards
defining the causes and mechanisms of this phenomenon. Leprosy and HIV co-infection can
present in various ways: a patient known to be HIV positive may develop signs of leprosy;
a leprosy patient may be diagnosed as HIV positive and a patient may present with leprosy
IRIS after starting HAART. Deps and Lockwood20 have recently proposed such a sub-
division attempting to separate unmasking episodes from those of overlap of immune
restoration. Four types of presentation of IRIS were identified
1. Unmasking – when patients develop leprosy or T1R after starting HAART. These patients
have not been diagnosed with leprosy. They are probably incubating leprosy and
the disease is only manifest after the immune restoration occurs. This was seen in 58%
of cases.
2. Overlap of immune restoration (paradoxical) – when leprosy has already been diagnosed
before starting HAART.WhenMDT and HAART are started within 3 months, T1R occurs
as a paradoxical reaction. This was seen in 10% of cases.
3. Undiagnosed leprosy or previously treated leprosy occurring at least 6 months before
HAART. When HAART is introduced, T1R occurs. This was seen in 10% of cases.
4. Unmasking followed by overlap of immune restoration after HAART and MDT – When
within 6 months after start HAART, leprosy has been diagnosed and MDT started.
Later the patient develops T1R. This was seen in 21% of cases.
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There are several possible mechanisms for the pathogenesis of leprosy IRIS. Leprosy
has a long incubation period and HAART may provide the immunological trigger of
normal disease. Another explanation is that leprosy-associated IRIS is similar to a T1R.
Whatever the underlying mechanisms, it is likely that leprosy-associated IRIS will be
increasingly reported, especially as access to HAART becomes more widely available. There
are also a number of case reports of patients being diagnosed with leprosy more than 6 months
after the initiation of HAART. Although these patients can present with any kind of leprosy,
including histoid leprosy,21 the time lag of greater than 6 months since the initiation of
HAART excludes the diagnosis of IRIS.
DOES BEING HIV POSITIVE AFFECT THE TREATMENT OF LEPROSY REACTION?
There is little good data on this. However leprosy patients, even if HIV positive, need
immuno-suppression for treating leprosy reactions and neuritis. There is substantial evidence
that leprosy reactions are an important part of the clinical disease picture seen in HIV/leprosy
co-infection. Patients being treated with steroids need careful monitoring to ensure that other
opportunistic infections such as tuberculosis and strongyloidiasis are detected early and
treated. The balance of benefit is for treating reactions to prevent nerve damage and disability.
Conclusion
There are currently no good prospective clinical data on the clinical features of leprosy in
HIV-infected patients, particularly the evolution of their skin lesions and progression of nerve
damage, and response to MDT. There is a need for prospective multi-centre studies, including
the African and Asian setting, with large numbers of patients and appropriate controls.
The inclusion of HIV testing in sentinel studies of patients relapsing after multidrug therapy
treatment would give some indication as to whether HIV infection is an important co-factor
in relapse. Response to treatment for neuritis and reaction in co-infected patients needs to
be studied carefully in prospective studies.
The influence of HIV infection on cell-mediated immune responses to M. leprae in the
HIV-infected patient needs exploration, especially within the skin. The recognition of leprosy
presenting as IRIS warrants immunological studies, using, for example, immunohistochem-
istry to delineate cellular phenotypes within the granuloma and mRNA and protein
production to assess cytokine expression.
The impact of leprosy and HIV co-infection is an evolving picture and further research is
needed to understand the mechanisms of disease and to develop better treatments.
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